Journal of Neurology

, Volume 259, Issue 4, pp 712–719 | Cite as

Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy

  • Atsushi Hashizume
  • Masahisa KatsunoEmail author
  • Haruhiko Banno
  • Keisuke Suzuki
  • Noriaki Suga
  • Fumiaki Tanaka
  • Gen SobueEmail author
Original Communication


Spinal and bulbar muscular atrophy (SBMA) is an adult-onset, X-linked motor neuron disease characterized by muscle atrophy, weakness, and bulbar involvement. The aim of this study was to analyze the differential change of various outcome measures by comparing the progression of motor impairment in the two independent groups: placebo-treated group (PTG) and natural history group (NHG). For the PTG, we analyzed 99 patients who participated in a previous double-blind phase III clinical trial and received placebo. For the NHG, a total of 34 patients were followed with no specific treatment. The characteristics of both groups did not differ at baseline except for disease duration. Although the 6 min walk distance (6MWD) showed almost the same progression in both groups (−14.7 ± 7.3 m in NHG, −14.0 ± 4.7 m in PTG; NS), there was a significant difference of progression in the ALSFRS-R between the NHG and PTG (−1.18 ± 0.38, −0.14 ± 0.24; p = 0.03). A similar tendency was also seen in the subgroup analysis of the patients whose disease durations were less than 10 years. Although the relationship between the ALSFRS-R and 6MWD at week 48 was similar to that at baseline in the NHG, the slope of the regression at week 48 was significantly milder than at baseline in the PTG (p = 0.04). In conclusion, these two groups demonstrated a large difference in the chronological analysis of a motor function score, but showed similar changes in objective measures of walking capacity. These findings should be thoroughly considered when designing clinical trials for slowly progressive neurodegenerative diseases such as SBMA.


Spinal and bulbar muscular atrophy Natural history Placebo effect Negative expectation Clinical trial 



We wish to thank all the JASMITT investigators for collecting data of PTG. We acknowledge and thank all patients and their families for participating in this study. We also acknowledge and wish to thank Hiroaki Oe and Shinya Sakai, the biostatisticians of EPS Co., Ltd., for statistical advice. This work was supported by the Program for Improvement of Research Environment for Young Researchers from Special Coordination Funds for Promoting Science and Technology (SCF) commissioned by the Ministry of Education, Culture, Sports, Science, and Technology of Japan; Grant-in-Aids from Ministry of Education, Culture, Sports, Science, and Technology of Japan (grant numbers 21689024 and 22110005); Large Scale Clinical Trial Network Project subsidized by the Ministry of Health, Labour and Welfare (MHLW) and supported by Health and Labour Sciences Research Grants, Japan; and JST, CREST, Japan.

Conflict of interest

G.S. has received research grant and honoraria from Takeda pharmaceuticals. All other authors declare that they have no conflict of interests.

Supplementary material

415_2011_6251_MOESM1_ESM.doc (82 kb)
Supplementary material 1 (DOC 82 kb)


  1. 1.
    Kennedy WR, Alter M, Sung JH (1968) Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18:671–680PubMedGoogle Scholar
  2. 2.
    Sperfeld AD, Karitzky J, Brummer D et al (2002) X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol 59:1921–1926PubMedCrossRefGoogle Scholar
  3. 3.
    Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A (1989) X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112(Pt 1):209–232PubMedCrossRefGoogle Scholar
  4. 4.
    Atsuta N, Watanabe H, Ito M et al (2006) Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 129(Pt 6):1446–1455PubMedCrossRefGoogle Scholar
  5. 5.
    La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77–79PubMedCrossRefGoogle Scholar
  6. 6.
    Fischbeck KH (1997) Kennedy disease. J Inherit Metab Dis 20:152–158PubMedCrossRefGoogle Scholar
  7. 7.
    La Spada AR, Taylor JP (2010) Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet 11:247–258PubMedCrossRefGoogle Scholar
  8. 8.
    Sobue G, Doyu M, Kachi T et al (1993) Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J Neurol Sci 117:74–78PubMedCrossRefGoogle Scholar
  9. 9.
    Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL (2002) Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59:770–772PubMedGoogle Scholar
  10. 10.
    Katsuno M, Adachi H, Kume A et al (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35:843–854PubMedCrossRefGoogle Scholar
  11. 11.
    Katsuno M, Adachi H, Doyu M et al (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9:768–773PubMedCrossRefGoogle Scholar
  12. 12.
    Takeyama K, Ito S, Yamamoto A et al (2002) Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35:855–864PubMedCrossRefGoogle Scholar
  13. 13.
    Chevalier-Larsen ES, O’Brien CJ, Wang H et al (2004) Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 24:4778–4786PubMedCrossRefGoogle Scholar
  14. 14.
    Banno H, Adachi H, Katsuno M et al (2006) Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Ann Neurol 59:520–526PubMedCrossRefGoogle Scholar
  15. 15.
    Banno H, Katsuno M, Suzuki K et al (2009) Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65:140–150PubMedCrossRefGoogle Scholar
  16. 16.
    Katsuno M, Banno H, Suzuki K et al (2010) Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:875–884PubMedCrossRefGoogle Scholar
  17. 17.
    Hróbjartsson A, Gøtzsche PC (2001) Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344:1594–1602PubMedCrossRefGoogle Scholar
  18. 18.
    Diederich NJ, Goetz CG (2008) The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 71:677–684PubMedCrossRefGoogle Scholar
  19. 19.
    The ALS (1996) CNTF treatment study (ACTS) phase I-II study group. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 53:141–147CrossRefGoogle Scholar
  20. 20.
    Ohashi Y, Tashiro K, Itoyama Y et al (2001) Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS (ALSFRS-R) Japanese version. No To Shinkei 53:346–355PubMedGoogle Scholar
  21. 21.
    Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M (1999) Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40. J Neurol 246(Suppl 3):III16–III21PubMedCrossRefGoogle Scholar
  22. 22.
    Jenkinson C, Fitzpatrick R (2001) Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5. J Neurol Neurosurg Psychiatry 70:70–73PubMedCrossRefGoogle Scholar
  23. 23.
    Yamaguchi T, Ohbu S, Saito M et al (2004) Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis–assessment questionnaire 40 (ALSAQ-40). No To Shinkei 56:483–494PubMedGoogle Scholar
  24. 24.
    Besinger UA, Toyka KV, Hömberg M et al (1983) Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33:1316–1321PubMedGoogle Scholar
  25. 25.
    Takeuchi Y, Katsuno M, Banno H et al (2008) Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 38:964–971PubMedCrossRefGoogle Scholar
  26. 26.
    Montes J, McDermott MP, Martens WB et al (2010) Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology 74:833–838PubMedCrossRefGoogle Scholar
  27. 27.
    Savci S, Inal-Ince D, Arikan H et al (2005) Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis. Disabil Rehabil 27:1365–1371PubMedCrossRefGoogle Scholar
  28. 28.
    Doyu M, Sobue G, Mukai E, Kachi T, Yasuda T, Mitsuma T, Takahashi A (1992) Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 32:707–710PubMedCrossRefGoogle Scholar
  29. 29.
    Rascol O (2009) “Disease-modification” trials in Parkinson disease: target populations, endpoints and study design. Neurology 72:S51–S58PubMedCrossRefGoogle Scholar
  30. 30.
    de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A (2010) A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:456–460PubMedCrossRefGoogle Scholar
  31. 31.
    Pascuzzi RM, Shefner J, Chappell AS et al (2010) A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:266–271PubMedCrossRefGoogle Scholar
  32. 32.
    Gordon PH, Moore DH, Miller RG et al (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6:1045–1053PubMedCrossRefGoogle Scholar
  33. 33.
    Pollo A, Benedetti F (2009) The placebo response: neurobiological and clinical issues of neurological relevance. Prog Brain Res 175:283–294PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Atsushi Hashizume
    • 1
  • Masahisa Katsuno
    • 1
    Email author
  • Haruhiko Banno
    • 1
    • 2
  • Keisuke Suzuki
    • 1
  • Noriaki Suga
    • 1
  • Fumiaki Tanaka
    • 1
  • Gen Sobue
    • 1
    Email author
  1. 1.Department of NeurologyNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Institute for Advanced ResearchNagoya UniversityNagoyaJapan

Personalised recommendations